Table 4.

Ongoing Clinical Trials of Vismodegib in Basal Cell Carcinoma

Study Title	Primary Endpoint	Enrollment (No.)	Estimated Completion Date
Phase 2 Multicenter, Single-Arm, Two-Cohort Trial Evaluating the Efficacy and Safety of GDC-0449 in Patients With Advanced Basal Cell Carcinoma	Overall response rate	15	December 2012
Phase 2 Multicenter, Open-Label, Two-Cohort Trial Evaluating the Efficacy and Safety of GDC-0449 in Operable Basal Cell Carcinoma (BCC)	Complete clearance rate (CCR) and durable complete clearance rate (DCCR) of target nodular BCC lesions at time of excision	49	December 2012
Randomized Phase 2 Multicenter Trial Evaluating the Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)	Reduction of new surgically eligible BCCs in BCNS patients during months 3–18 of ingestion of vismodegib 150 mg/day	41	March 2013
Single-Arm, Open-label, Phase 2 Multicenter Study to Assess the Safety of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)	Incidence of adverse events	150	September 2013

Data from ClinicalTrials.gov.